| Grab Sources And More Here: Company Website. Company Presentation. -----
As mentioned above, (NYSE American: MAIA) has several explosive potential catalysts to consider right now. Check these out:
#1. MAIA Potential Catalyst - One Analyst's Target Suggests Over 850% Potential Upside From MAIA's Current Chart Levels.
This month, Robert LeBoyer, Senior Vice President and equity research analyst with Noble Life Science Partners, reiterated a $14.00 target on MAIA.
From Thursday's closing valuation, that provides MAIA with upside potential over 850%!
Check out some key report highlights:
Conclusion. We believe the clinical progress from the Phase 2 trial have not been reflected in the st-ock price. Data from the Phase 2 THIO-101 Expansion/Registration patients could lead to an application for Early Approval, as well as confirm our high probability of Phase 3 success. We are reiterating our Outperform rating and $14 price target. -----
#2. MAIA Potential Catalyst - Another Analyst Target Suggests Over 600% Potential Upside From Thursday's Close.
Also this month, an analyst at Diamond Equity Research provided an update note on their (NYSE American: MAIA) coverage.
In the update, they retagged MAIA with a target of $10.27.
From Thursday's close, that target provides MAIA with a potential upside of over 600%.
Here's some highlights from the report:
Valuation: Recent clinical updates include THIO-101 Phase 2 data (180 mg dose cohort) showing median PFS of 5.6 months (>2x SOC) and median OS of 17.8 months, with two patients completing 33 cycles, as well as ESMOhighlighted 30-month survival in a refractory NSCLC patient completing two year therapy. With continued positive readouts, the ongoing THIO-104 Phase 3 study remains a key valuation catalyst, marking progression toward controlled clinical validation and potential registration. We maintain our valuation of $10.27 per share, contingent on successful execution by the company. -----
#3. MAIA Potential Catalyst - A Key Shareholder Letter Highlights The Substantial Commercial Potential For Ateganosine In A $50Bn Market.
MAIA Biotechnology’s Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opp. in $50Bn Immunotherapy Market
Ongoing Phase 3 full approval clinical trial of ateganosine holds high probability of technical success for interim and full analysis
FDA Fast Track designation offers clear pathway for ateganosine as third-line therapy for non-small cell lung cancer (NSCLC)
First and only direct telomere-targeting anticancer agent in clinical development anywhere
MAIA CEO details development pipeline in letter to shareholders
CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today published a 2026 Letter to Shareholders by Founder and CEO Vlad Vitoc, M.D. featuring the Company’s strong momentum in clinical trials of its lead molecule, ateganosine, as a treatment for non-small cell lung cancer (NSCLC). As a potential breakthrough therapy, ateganosine holds substantial commercial opp. in a $50Bn global immunotherapy market.
As stated in the Letter, Dr. Vitoc wrote, “Our development strategy intentionally targets the third-line (3L) NSCLC population, where the unmet need is urgent. No established standard of care exists in 3L treatment, with most oncologists currently treating 3L patients with chemotherapy, leading to particularly poor clinical outcomes. In clinical studies, ateganosine sequenced with an immune checkpoint inhibitor (CPI) has demonstrated outcomes that exceed those historically achieved with either CPI-based therapy or chemotherapy alone. These findings position ateganosine not as a competitor to CPIs, but as the foundation of a new treatment category designed specifically for advanced NSCLC following CPI and chemotherapy failure. By focusing on a third-line population with no defined standard of care, we are addressing an underserved group of approximately 50,000 patients annually in the United States and creating a differentiated, incremental revenue opp. outside of the CPI market.”
“Ateganosine could mark the start of a new therapeutic category in cancer treatment and could become the standard of care for multiple cancer indications,” Dr. Vitoc added. “The commercial opp. for ateganosine could be immense.”
...
Read the full article here. -----
#4. MAIA Potential Catalyst - The Company Targets Key 2026 Clinical Milestones (High Probability Of Technical Success In Pivotal Phase 3 Trial).
MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum
High probability of technical success in pivotal Phase 3 trial based on unmatched efficacy data for third-line non-small cell lung cancer (NSCLC) treatment
FDA’s Fast Track designation for ateganosine in NSCLC advances concurrent Phase 2 expansion and Phase 3 trials along strategic regulatory pathways
Strong momentum toward goal of early commercial approval
Potential breakthrough therapeutic for estimated $50+Bn global immunotherapy market; first and only telomere-targeting anticancer agent in clinical development anywhere
CHICAGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today provided a corporate update on 2025 achievements and highlighted key targeted milestones and growth catalysts for 2026.
“MAIA’s strong clinical execution in 2025 delivered exceptional efficacy data for ateganosine sequenced with a checkpoint inhibitor, including disease control, response rates, and survival data well above standard of care benchmarks,” said MAIA founder and CEO Vlad Vitoc, M.D. “The results clearly differentiate our novel telomere-targeting science and support the U.S. FDA’s Fast Track designation granted in 2025, positioning ateganosine for potential eligibility under the Accelerated Approval and Priority Review regulatory pathways.
Our statistical assessments of ateganosine imply a high probability of technical success in our concurrent Phase 3 and Phase 2 trials. As our first-in-class small molecule advances toward potential early commercial approval—possibly within 18 to 24 months—we believe our strong execution is driving a clear value-creation inflection point, with meaningful long-term benefits for stockholders.”
...
Targeted 2026 Milestones
Initial measures of efficacy from Phase 3 study. Interim disease control rates (DCR), overall response rates (ORR) and progression free survival (PFS) analysis of ateganosine compared to the control arm will support regulatory discussions. Strong interim data could lead to early full commercial approval.
Conclusion of Part C of Phase 2 study. Expansion of the trial provides additional clinical efficacy data to support regulatory review for commercial approval.
Engage in regulatory interactions with the FDA. Expand ongoing FDA dialogue under the Fast Track designation, including discussions around trial enhancements and prospects for Accelerated Approval and Priority Review.
Clinical development of second-generation molecules to start in Phase 1 trials. Additional small molecules fully developed in-house with better expected efficacy compared to ateganosine.
Read the full article here. -----
#5. MAIA Potential Catalyst - Multiple Oversold Leaning Technical Indicators Could Suggest A Healthy Reversal May Be Nearing.
At 4:00PM EST Thursday, Barchart was reporting MAIA to possess several oversold leaning technical indicators.
These technicals could be signaling a healthy reversal is approaching in the near term.
Here's the definition of a "reversal" from Investopedia:
"A reversal is a change in the price direction of an asset. A reversal can occur to the upside or downside. Following an uptrend, a reversal would be to the downside. Following a downtrend, a reversal would be to the upside. Reversals are based on overall price direction and are not typically based on one or two periods/bars on a chart."
Here are the technicals to pay close attention to (as of 4:00PM EST Thursday):
- 9-Day Relative Strength Index: 31.07%
- 14-Day Relative Strength Index: 36.01%
When these numbers drop down to the 30% range and lower, they can be viewed as being in oversold territory. While in this territory, they can paint the picture of a profile that is undervalued.
- 9-Day Raw Stochastic %D: 16.67%
- 14-Day Raw Stochastic %D: 13.33%
As the Raw Stochastic nears the 10% range and lower it may also be viewed as oversold and undervalued.
Keep an eye on these technicals closely. -----
MAIA Recap - This NYSE American Breakout Idea Has 5 Explosive Potential Catalysts
#1. One Analyst's Target Suggests Over 850% Potential Upside From MAIA's Current Chart Levels.
#2. Another Analyst Target Suggests Over 600% Potential Upside From Thursday's Close.
#3. A Key Shareholder Letter Highlights The Substantial Commercial Potential For Ateganosine In A $50Bn Market.
#4. The Company Targets Key 2026 Clinical Milestones (High Probability Of Technical Success In Pivotal Phase 3 Trial).
#5. Multiple Oversold Leaning Technical Indicators Could Suggest A Healthy Reversal May Be Nearing. -----
Coverage is a "Go" on MAIA Biotechnology, Inc. (NYSE American: MAIA).
When updates are available, we'll get them out quickly. Talk soon.
Sincerely, Kai Parker StockWireNews
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
*StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 03/27/2026 and ending on 03/27/2026 to publicly disseminate information about (MAIA:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC twenty thousand USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid one hundred ninety one thousand two hundred fifty USD ("Funds"). These Funds were part of the one hundred ten thousand USD funds that TD Media LLC received from a third party named Sica Media LLC who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither SWN Media LLC, TD Media LLC and their member own shares of (MAIA:US).
Please see important disclosure information here: https://stockwirenews.com/disclosure/maia-4wvwp/#details | 
